1. EMA. Summary of posaconazole characteristics. 2022 January 6, 2022. https://www.ema.europa.eu/en/documents/product-information/noxafil-epar-product-information_en.pdf. Accessed 1 Feb 2022.
2. European Committee on Antimicrobial Susceptibility Testing. Posaconazole: rationale for the EUCAST clinical breakpoints, version 3.0. 4 February, 2020. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Posaconazole_RD_v3.0_final_final_18_02.pdf. Accessed 1 Feb 2022.
3. FDA. Noxafil instruction. March 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205053s1lbl.pdf. Accessed 1 Feb 2022.
4. Chen L, Krekels EHJ, Verweij PE, Buil JB, Knibbe CAJ, Brüggemann RJM. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs. 2020;80(7):671–95.
5. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Topelt K, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50(2):658–66.